Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression.

Journal of clinical psychopharmacology

Zilcha-Mano S, Wang X, Wajsbrot DB, Boucher M, Fine SA, Rutherford BR.
PMID: 34183490
J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):579-584. doi: 10.1097/JCP.0000000000001435.

PURPOSE/BACKGROUND: Heterogeneity has been documented in trajectories of symptom change during antidepressant treatment for major depressive disorder (MDD). It is unclear whether distinct trajectories of change exist for functioning during antidepressant treatment.METHODS/PROCEDURES: This analysis explored distinct trajectories of functioning...

Cite
Zilcha-Mano S, Wang X, Wajsbrot DB, et al. Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression. J Clin Psychopharmacol. 2021;41(5):579-584doi: 10.1097/JCP.0000000000001435.
Zilcha-Mano, S., Wang, X., Wajsbrot, D. B., Boucher, M., Fine, S. A., & Rutherford, B. R. (2021). Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression. Journal of clinical psychopharmacology, 41(5), 579-584. https://doi.org/10.1097/JCP.0000000000001435
Zilcha-Mano, Sigal, et al. "Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression." Journal of clinical psychopharmacology vol. 41,5 (2021): 579-584. doi: https://doi.org/10.1097/JCP.0000000000001435
Zilcha-Mano S, Wang X, Wajsbrot DB, Boucher M, Fine SA, Rutherford BR. Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):579-584. doi: 10.1097/JCP.0000000000001435. PMID: 34183490; PMCID: PMC8407446.
Copy Download .nbib Format: NLM
The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence.

Addictive behaviors reports

Crawford G, Jao N, Peng AR, Leone F, Kalhan R, Tyndale RF, Weisbrot J, Hitsman B, Schnoll R.
PMID: 29998189
Addict Behav Rep. 2018 Jul 04;8:46-50. doi: 10.1016/j.abrep.2018.06.006. eCollection 2018 Dec.

INTRODUCTION: The degree to which smokers quit successfully with varenicline is strongly associated with their adherence to the medication regimen. Thus, measuring varenicline adherence to identify smokers needing additional intervention is a priority. Few studies, however, have examined the...

Cite
Crawford G, Jao N, Peng AR, et al. The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence. Addict Behav Rep. 2018;8:46-50doi: 10.1016/j.abrep.2018.06.006.
Crawford, G., Jao, N., Peng, A. R., Leone, F., Kalhan, R., Tyndale, R. F., Weisbrot, J., Hitsman, B., & Schnoll, R. (2018). The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence. Addictive behaviors reports, 846-50. https://doi.org/10.1016/j.abrep.2018.06.006
Crawford, Grace, et al. "The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence." Addictive behaviors reports vol. 8 (2018): 46-50. doi: https://doi.org/10.1016/j.abrep.2018.06.006
Crawford G, Jao N, Peng AR, Leone F, Kalhan R, Tyndale RF, Weisbrot J, Hitsman B, Schnoll R. The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence. Addict Behav Rep. 2018 Jul 04;8:46-50. doi: 10.1016/j.abrep.2018.06.006. eCollection 2018 Dec. PMID: 29998189; PMCID: PMC6037908.
Copy Download .nbib Format: NLM
Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.

Infectious diseases and therapy

Mazuski JE, Wagenlehner F, Torres A, Carmeli Y, Chow JW, Wajsbrot D, Stone GG, Irani P, Bharucha D, Cheng K, Tawadrous M.
PMID: 34374952
Infect Dis Ther. 2021 Dec;10(4):2399-2414. doi: 10.1007/s40121-021-00506-7. Epub 2021 Aug 10.

INTRODUCTION: This exploratory analysis assessed efficacy and safety outcomes in patients with Gram-negative bacteremia treated with ceftazidime-avibactam or comparator across five phase 3, randomized, controlled, multi-center trials in adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI)/pyelonephritis,...

Cite
Mazuski JE, Wagenlehner F, Torres A, et al. Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infect Dis Ther. 2021;10(4):2399-2414doi: 10.1007/s40121-021-00506-7.
Mazuski, J. E., Wagenlehner, F., Torres, A., Carmeli, Y., Chow, J. W., Wajsbrot, D., Stone, G. G., Irani, P., Bharucha, D., Cheng, K., & Tawadrous, M. (2021). Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infectious diseases and therapy, 10(4), 2399-2414. https://doi.org/10.1007/s40121-021-00506-7
Mazuski, John E, et al. "Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program." Infectious diseases and therapy vol. 10,4 (2021): 2399-2414. doi: https://doi.org/10.1007/s40121-021-00506-7
Mazuski JE, Wagenlehner F, Torres A, Carmeli Y, Chow JW, Wajsbrot D, Stone GG, Irani P, Bharucha D, Cheng K, Tawadrous M. Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infect Dis Ther. 2021 Dec;10(4):2399-2414. doi: 10.1007/s40121-021-00506-7. Epub 2021 Aug 10. PMID: 34374952; PMCID: PMC8353612.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries